



PRESS RELEASE DECEMBER 3rd 2010

PUBLICATION OF SUPPLEMENT TO PROSPECTUS REGARDING OFFER TO SUBSCRIBE FOR SHARES IN MOBERG DERMA AB (PUBL.)

Today Moberg Derma AB (publ.) ("Moberg Derma") has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared following the press release on 3 December 2010 in which Moberg Derma announces that Moberg Derma has signed an agreement for distribution in Switzerland.

The supplementary prospectus, which has been approved and registered with the Swedish Financial Supervisory Authority, must be read together with the prospectus in all parts. The supplementary prospectus and the prospectus are available electronically on Moberg Derma's website, www.mobergderma.se and on E. Öhman J:or Fondkommission AB's website, www.ohman.se.

Those investors who have applied for subscription of shares before the publication of the supplementary prospectus are, in accordance with Chapter 2, Section 34 of the Swedish Financial Instruments Trading Act of 1991, entitled to withdraw their application within five working days from the publication of the supplementary prospectus, i.e. no later than on 10 December 2010. As a consequence, the subscription period is thereby extended until CET 17.00 on 10 December 2010. New first day of trading on NASDAQ OMX Stockholm is estimated to 13 December 2010 and settlement date is estimated to 16 December 2010.

For further information, please contact:

Peter Wolpert, President and CEO of Moberg Derma

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The Company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management.

For further information, please visit: www.mobergderma.se